184 related articles for article (PubMed ID: 34881848)
21. Preclinical evaluation of investigational radiopharmaceutical RISAD-P intended for use as a diagnostic and molecular radiotherapy agent for prostate cancer.
Kortylewicz ZP; Mack E; Enke CA; Estes KA; Mosley RL; Baranowska-Kortylewicz J
Prostate; 2015 Jan; 75(1):8-22. PubMed ID: 25283970
[TBL] [Abstract][Full Text] [Related]
22. Targeted radionuclide therapy--an overview.
Dash A; Knapp FF; Pillai MR
Curr Radiopharm; 2013 Sep; 6(3):152-80. PubMed ID: 24059327
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic radionuclides in nuclear medicine: current and future prospects.
Yeong CH; Cheng MH; Ng KH
J Zhejiang Univ Sci B; 2014 Oct; 15(10):845-63. PubMed ID: 25294374
[TBL] [Abstract][Full Text] [Related]
24. Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy.
Fahey F; Zukotynski K; Jadvar H; Capala J;
J Nucl Med; 2015 Jul; 56(7):1119-29. PubMed ID: 25999432
[No Abstract] [Full Text] [Related]
25. Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents.
Nurhidayah W; Setyawati LU; Daruwati I; Gazzali AM; Subroto T; Muchtaridi M
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432107
[TBL] [Abstract][Full Text] [Related]
26. Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer.
Baratto L; Duan H; Mäcke H; Iagaru A
J Nucl Med; 2020 Jun; 61(6):792-798. PubMed ID: 32060215
[TBL] [Abstract][Full Text] [Related]
27. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
28. Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.
Winuprasith T; Koirala P; McClements DJ; Khomein P
Int J Nanomedicine; 2023; 18():4449-4470. PubMed ID: 37555189
[TBL] [Abstract][Full Text] [Related]
29. The production of no-carrier-added radiopharmaceuticals with special reference to radionuclide impurities.
Lagunas-Solar MC
Int J Nucl Med Biol; 1983; 10(2-3):75-84. PubMed ID: 6642897
[TBL] [Abstract][Full Text] [Related]
30. Theragnostic in neuroendocrine tumors.
Marini I; Sansovini M; Bongiovanni A; Nicolini S; Grassi I; Ranallo N; Monti M; DI Iorio V; Germanò L; Caroli P; Sarnelli A; Paganelli G; Severi S
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):342-352. PubMed ID: 34881852
[TBL] [Abstract][Full Text] [Related]
31. Molecular radiotheragnostics in prostate cancer.
Du Y; Dizdarevic S
Clin Med (Lond); 2017 Oct; 17(5):458-461. PubMed ID: 28974599
[TBL] [Abstract][Full Text] [Related]
32. PET imaging in urology: a rapidly growing successful collaboration.
Farolfi A; Koschel S; Murphy DG; Fanti S
Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721
[TBL] [Abstract][Full Text] [Related]
33. Molecular radiotheragnostics in thyroid disease.
Singh N; Lewington V
Clin Med (Lond); 2017 Oct; 17(5):453-457. PubMed ID: 28974598
[TBL] [Abstract][Full Text] [Related]
34. Nuclear Medicine in Pediatric and Adolescent Tumors.
Kiratli PÖ; Tuncel M; Bar-Sever Z
Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
[TBL] [Abstract][Full Text] [Related]
35. [Draft guideline regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine].
Kinuya S; Yoshinaga K; Higuchi T; Jinguji M; Kawamoto H; Kurihara H
Kaku Igaku; 2015 Feb; 52(1):1-15. PubMed ID: 26502667
[TBL] [Abstract][Full Text] [Related]
36. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer radiopharmaceuticals.
Hoefnagel CA
Anticancer Drugs; 1991 Apr; 2(2):107-32. PubMed ID: 1958857
[TBL] [Abstract][Full Text] [Related]
38. Updated Review of Nuclear Molecular Imaging of Thyroid Cancers.
Fu H; Sa R; Cheng L; Jin Y; Qiu X; Liu M; Chen L
Endocr Pract; 2021 May; 27(5):494-502. PubMed ID: 33934754
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in nuclear medicine in endocrine oncology.
Luster M; Pfestroff A; Verburg FA
Curr Opin Oncol; 2017 Jan; 29(1):1-6. PubMed ID: 27906859
[TBL] [Abstract][Full Text] [Related]
40. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
